CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

MITY Inc.

MITY Incorporated is a worldwide leader in helping customers optimize their facilities with innovative furniture solutions. Our product brands MityLite®, Holsag®, Bertolini®, and XpressPort®. The products manufactured by our brands deliver the safety, ease of use, and functional design needed for businesses in industries such as hospitality, worship, education, senior living, restaurant, and government. With worldwide headquarters in Orem, Utah operating since 1987, MITY now has offices and manufacturing facilities in Tennessee, Missouri, and Ontario. QUALITY ENGINEERING: Detailed design and superior manufacturing go into every product built by MITY product brands. We stand by our strong warranty program and commitment to excellent customer service. INNOVATIVE PRODUCTS: ABS Folding Tables, stacking banquet chairs, folding chairs, portable dance floors, mobile banquet tables, and linenless tables with integrated power—we offer the best! OUR SECRET SAUCE: We have the most elite, creative, and passionate team of employees in the industry! They are committed to serving our business partners. Interested in joining our team or doing business with MITY? Email info@mityinc.com or call 800-909-8034.

Ascend

Ascend empowers entrepreneurial CPAs to reach their goals with an innovative growth model that brings their firms into the new age. Backed by private equity from people-focused Alpine Investors, Ascend is building a modern platform for regional accounting firms that enables them to stay independent while accessing the resources of a large CPA firm to help them grow. Ascend provides access to growth capital, robust talent acquisition, best-of-breed technology, a catalytic leadership system, shared back-office services, and modernized equity incentives so that firms can surmount todays industry challenges and reach their full potential. Founded in January 2023, the company attained revenues sufficient to qualify it as a Top 100 U.S. accounting firm within six months of operation.

Balboa Solutions

We provide seamless, hands-on management and strategic guidance to help you unlock the full potential of your Pendo investment. From setup to optimization, our team ensures cleaner data, stronger engagement, and measurable results for your business.

Bradesco Bank

Bradesco Bank is a Member FDIC Equal Housing Lender. With over 50 years of experience catering to the financial needs of individual, corporate and institutional customers, our products and services have been carefully structured to serve the domestic and international markets, which, combined with our personalized service, ensures that your experience with Bradesco Bank will be unparalleled. For more information, please access: http://www.bradescobank.com

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.